Product Description
CPB545 is a 2+2 symmetric tetravalent bispecific engineered to simultaneously target mouse programmed cell death protein 1 (PD-1, CD279) and mouse or human vascular endothelial growth factor A (VEGF-A) proteins. CPB545 contains the murine IgG2a constant region to reduce immunogenicity and the formation of anti-drug antibodies (ADAs) in mouse models and LALA-PG Fc-silencing mutations to abolish antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) while minimizing Fc-driven off-target toxicity. This bispecific was designed to concurrently block two key pathways involved in tumor progression and immune evasion through dual PD-1 and VEGF-A inhibition. The tetravalent structure provides four antigen-binding sites to enable cooperative binding that can leverage target proximity within the tumor microenvironment.
* VAT and shipping costs not included. Errors and price changes excepted
